title: Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
authors.forename: Juliana Helena
authors.initials: JH
authors.lastname: Oliveira
authors.forename: Cristof
authors.initials: C
authors.lastname: Kazda
authors.forename: Alexander
authors.initials: A
authors.lastname: Simpson
authors.forename: Jeffrery A
authors.initials: JA
authors.lastname: Jackson
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Heine
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005215:Fasting / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D061268:Insulin Lispro; D049528:Insulin, Long-Acting
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine